| 22-01-07 | Delisting of AS "Olainfarm” shares from the Baltic Main list | AQ |
| 22-01-06 | Notification about results of final buy-back of shares | AQ |
| 21-12-30 | Notification about final share buy-back | AQ |
| 21-12-28 | Correction: Regarding results of a share buy-back offer | AQ |
| 21-12-28 | On substantial participation (4) - specified | AQ |
| 1 day | -0.24% |
| Manager | Title | Age | Since |
|---|---|---|---|
Juris Hmelnickis
CEO | Chief Executive Officer | 46 | 2025-12-31 |
Janis Leimanis
DFI | Director of Finance/CFO | 56 | - |
| Chief Tech/Sci/R&D Officer | - | 2009-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 2021-06-18 | |
Janis Buks
CHM | Chairman | - | 2022-08-31 |
Roberts Tavjevs
BRD | Director/Board Member | - | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.24% | -3.46% | - | - | 148M | |
| +0.44% | +0.32% | +6.24% | +82.35% | 44.99B | |
| -0.44% | -7.89% | +40.02% | +89.26% | 33.69B | |
| +0.69% | +2.72% | +12.64% | +117.80% | 11.6B | |
| +0.46% | +0.59% | -8.44% | +42.72% | 11.68B | |
| 0.00% | +0.39% | +36.17% | +125.55% | 8.94B | |
| -1.44% | -2.92% | +15.81% | +39.35% | 7.01B | |
| +0.00% | -1.36% | +32.74% | +237.16% | 6.35B | |
| +0.61% | +3.68% | +45.01% | -16.20% | 6.51B | |
| -0.45% | -3.68% | -38.58% | -6.82% | 5.15B | |
| Average | -0.04% | -0.93% | +15.73% | +79.02% | 15.1B | |
| Weighted average by Cap. | +0.07% | -1.81% | +17.76% | +83.44% |
Employees
2,191
Sector
Pharmaceuticals
